Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x. x č. 46/2008 Xx. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx dne 1. října 2017 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx schválení xxxxxx znění Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx dopingu pro xxx 2018 - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx X x xxxxxxxx xxx 5. června 2019.

Xxxx xxxxxx nového xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx od 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Anglické xxxxx nového xxxxx Xxxxxxx X a xxxx xxxxxxx do xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX ROK 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X případě xxxxxxxxxxx xxxxxxxxx xxxx anglickou x francouzskou xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx od 1. xxxxx 2018 

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX XXX 2018

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2018

XXXXX A XXXXXX XXXXXXXX STÁLE (PŘI SOUTĚŽI X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXXXXX XXXXX

X0. NESCHVÁLENÉ XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx sekcích Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (např. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx stále.

S1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky.

b. Xxxxxxxxx** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx a xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. xxxxxxx, LGD-4033, xxxxxxx x XXX140); tibolon; xxxxxxx x xxxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

Xxx účely skupiny xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, kterou xxxx xxxxxxxx přirozeně xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (EPO) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, ale xx x xxxxxxxx xxxxx xx ně:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); erytropoetiny (XXX); xxxxxxxxxx xxxxxxxx na XXX (EPO-Fc, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x jejich xxxxxxxxxx (xxxx. XXXX 530 x peginesatid).

1.2 Xxxxxxxxx prostředky hypoxii xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; sotatercept.

1.5 Xxxxxxxx vrozeného opravného xxxxxxxxx. např.

asialo XXX; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Choriogonadotropin (XX) x xxxxxxxxxxxx xxxxxx (XX) a xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx, x xxxx.

2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Růstový xxxxxx (GH), xxxx xxxxxxxxx x uvolňující xxxxxxx, xxxxxx, ale xx x omezením xxxxx xx ně:

fragmenty xxxxxxxxx hormonu, např. XXX-9604 x xXX 176-191; xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x jeho analoga, xxxx. XXX-1295, sermorelin x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, např. xxxxxxxxxx, xxxxxxxxxx a xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (GHRP), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, GHRP-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1) a xxxx analoga

mechanické růstové xxxxxxx (MGF);

růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX).

Xxxxx růstové xxxxxxx a xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x vaziva, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- AGONISTÉ

Všichni xxxxxxxxxx i xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx isomerů, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx na xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; terbutalin; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, nepřekračujících 800 xxxxxxxxxx během každých 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx v moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx než 40 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx abnormální xxxxxxxx xxx xxxxxxxx terapeutickou xxxxxx (x xxxxxxxx) xxxxx, než xxxx xxxxxxx maximální dávka.

S4. XXXXXXXXX A METABOLICKÉ XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx ne x xxxxxxxx xxxxx xx xx.

3. Ostatní xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, ale xx s xxxxxxxx xxxxx na xx.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) kyselina xxxxxx (XX1516, GW501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x xxxxxxxxx biologickými xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; furosemid; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx a xxxxxxx (xxxx. xxxxxxxxx), xxx xx s xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu a xxxxxx xxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx podání xxxxxxxxxxxx pro zubní xxxxxxxxx

Xxxxx xxxxxxxxxxx množství xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) ve Xxxxxx Xxxxxxxxx kdykoliv nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, pokud Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx již xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx krvinek x jim xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx x mikroenkapsulované hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), ale ne x xxxxxxxx xxxxx xx xx. Inhalační xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Jakákoliv forma xxxxxxxxxxxxxxx manipulace s xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, nebo Pokus x Xxxxxx, xx xxxxxx xxxxxxx integritu x platnost Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. To xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx celkem 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx diagnostických xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx geneticky xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x xxxxxxxxxxxx xxxx epigenetické xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 x X1 až X3 xxxxxxxxx výše

jsou Xxx Xxxxxxx zakázané i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx případných xxxxxxxxx isomerů, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx stimulancia:

Adrafinil;

amfepramon;

amfetamin;

amfetaminil;

amifenazol;

benfluorex;

benzylpiperazin;

bromantan;

fendimetrazin;

fenetylin;

fenfluramin;

fenkamin;

fenproporex;

fentermin;

fonturacetam /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx látkou.

(b) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (metylsynefrin);

pemolin;

pentetrazol;

propylhexedrin;

pseudoefedrin*****;

selegilin;

sibutramin;

strychnin;

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx místního/očního xxxxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol x synefrin: Xxxx xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2018 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Katin: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší xxx 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx a methylefedrin: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 mikrogramů x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx xxxx xxxx xxxxxx společně x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx kanabinoidy xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, konopí x xxxxxxxxx.

• Xxxxxxxxxx xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (THC) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx orálně, rektálně, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX XXXXXXXX X&xxxx;XXXXXXXX XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x kde xx xx xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx air"

• Podvodní xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx bez xxxxxxx, free xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx xx xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. nabyl xxxxxxxxx xxxx 26.7.2019.

Právní předpis x. 36/2019 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx jiných xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.

1) Mezinárodní úmluva xxxxx xxxxxxx ve xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx v xxxxxxxxx xxxxx x s xxxxxxxxx xx českého xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Xxxxxx xx xxxxxxx xxxxxx xxxx vyhlášeno xxx č. 46/2008 Sb. m. s.